ALZN earnings: next report 2026-09-09, real EPS beat/miss history, analyst consensus Buy, P/E -0.29. Updated 2026-07-23.
Alzamend Neuro (ALZN) Research Hub
Alzamend Neuro (ALZN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.72 USD (+2.38%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.29, market cap 0.00B. This hub links to the full technical, earnings and options research available for ALZN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.72 USD (+2.38%) |
| 52-week range | 1.06 USD – 1.74 USD |
| Trend regime | Range |
| 14-day RSI | 77.8 (Overbought) |
| Trailing P/E | -0.29 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-09 |
Available research for ALZN
Covered Call on ALZN: how it works, illustrative setup around the real 1.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALZN: how it works, illustrative setup around the real 1.72 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALZN: how it works, illustrative setup around the real 1.72 USD price, max profit/loss, breakeven and when to use it. Educational.
ALZN technical analysis: range, last 1.72 USD, RSI 77.8, 52w range 1.06 USD–1.74 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALZN in?
Alzamend Neuro (ALZN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALZN in an uptrend or downtrend?
As of 2026-09-11, ALZN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALZN's trailing P/E ratio?
ALZN's trailing P/E is -0.29, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ALZN next report earnings?
ALZN is next scheduled to report earnings on 2026-09-09, with a consensus EPS estimate of -0.67 USD.